Navigation Links
New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
Date:9/19/2007

f greater than or equal to 1.41% for lumbar spine and greater than or equal to 0.87% for total hip.

The primary efficacy analysis was based on the per protocol population. By 12 months, increase in average lumbar spine BMD was 5.10% among those taking Boniva and 5.78% among those taking Fosamax. Increase in average total hip BMD was 2.94% and 3.03%, respectively. In addition, treatment with Boniva versus Fosamax provided comparable increases in BMD at the trochanter (4.2% for both) and in the femoral neck (2.1% vs. 2.3%, respectively, in a post-hoc analysis). A low BMD is one of the most important underlying causes of fractures in older adults. However, fracture was not an efficacy endpoint in the trial.

In the safety analysis, the overall incidence of adverse events was similar between the treatment groups. The most frequently reported adverse events (reported by at least 5% of women in either treatment group) included hypertension, dyspepsia, back pain, arthralgia, nasopharyngitis, and influenza. Of the serious adverse events, less than 1% per group were considered treatment related.

About Osteoporosis

Osteoporosis (porous bones) is a disease in which bones become brittle and more likely to break. In the U.S. today, 10 million people -- eight million of them women -- are estimated to already have osteoporosis, and almost 34 million more are estimated to have low bone mass (osteopenia) placing them at increased risk for osteoporosis. Unfortunately, the prevalence of osteoporosis is growing, especially as the number of postmenopausal women in the population continues to rise. Together, osteoporosis and osteopenia are expected to affect an estimated 52 million women and men age 50 and older by 2010, and 61 million by 2020. Direct medical costs of osteoporosis total nearly $18 billion in the U.S. each year.

About Once-Monthly Oral Boniva

Boniva is indicated for the treatment and prevention of osteoporosis in postmenopausal women. In
'/>"/>

SOURCE Roche and GSK
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sep. 03, 2015 Research ... the "Investigation Report on China,s Trastuzumab Market, 2010-2019" ... Genentech, trastuzumab was approved by FDA to be used ... name of Herceptin, a major product of Roche. In ... billion around the world. After entering ...
(Date:9/3/2015)... , Sep. 03, 2015 ... announced the addition of the "Global Craniomaxillofacial ... offering. The global craniomaxillofacial devices market ... 2014-2019. This report covers the present and ... for 2015-2019. To calculate the market size, we ...
(Date:9/3/2015)... 3, 2015 China,s ... Monitoring Patch, a wearable medical device that can continuously ... data, providing safety guidance for pregnant women. The device ... The device, which measures 4 centimeters in diameter, is ... little more than an Apple earphone cord. The small ...
Breaking Medicine Technology:Investigation Report on China's Trastuzumab (Genentech) Market, 2010-2019 2Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2
... 25, 2011 Newport Audiology Centers announced ... Colorado, to Nashville, Tennessee. The new Nashville Operations Center ... its key partners and expand operations across their consumer, ... are very excited by the opportunities Nashville will bring," ...
... China, July 25, 2011 /PRNewswire-Asia/ -- The whole healthcare ... technology trends and social economic increases. Generally speaking, several ... rapid increase of world population especially the aging ... are increasing in both developed and developing countries. They ...
Cached Medicine Technology:Avoid Illness Through Easy Daily Check 2
(Date:9/3/2015)... ... , ... William Mattar Law Offices is known for its slogan “Helping People, ... any certain demographic or segment of the population. Because of this, the firm ... commercials. , The closed captioning will allow people with hearing impairments or who are ...
(Date:9/3/2015)... ... September 03, 2015 , ... The Beryl ... Conference 2016, to be held April 13-15 at Sheraton Hotel in Dallas, Texas. ... together the collective voices of healthcare leaders, staff, physicians, patients and families across ...
(Date:9/3/2015)... ... September 03, 2015 , ... DriButts, a non-profit organization dedicated ... Product Development Group to manufacture a long-lasting reusable diaper for warm weather climates ... to bring 600 DriButts Diapers to rural areas of Haiti during a trip ...
(Date:9/3/2015)... ... ... Real Time Pain Relief (RTPR), makers of the popular rub-on pain ... an official endorsement deal with the company. Originally from New South Wales, Australia, Mason ... 15. He is an Australian bull riding champion, following in his uncles’ footsteps in ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations ... for 2015 by economic development group GrowFL and the Edward Lowe Foundation. The ... selected for this prestigious award, which recognizes growing second-stage companies “that demonstrate high ...
Breaking Medicine News(10 mins):Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
... for Dental Research (AADR) is presenting an honorary membership ... at the AADR/Research!America Advocacy Day, March 2, 2010, in ... his commitment to the National Institutes of Health (NIH) ... (NIDCR). He remains one of the Senate,s most staunch ...
... that reward workers for meeting certain performance measures for ... use a variety of methods to reward physicians financially ... A new study in the Journal for ... be effective in incentivizing low performing physicians. The article ...
... aimed at helping with planning efforts for a public ... the Harvard School of Public Health (HSPH) have found ... significant anthrax attack in their city or town, most ... obtain prophylactic antibiotics. However, a significant minority of those ...
... ... was featured in a national study of high performance services firms entitled “The High Growth ... , ... 2010 -- Webmarketing 123, a San Francisco Bay Area based search engine marketing firm, was ...
... suggests , FRIDAY, Feb. 19 (HealthDay News) -- In the ... identified a defective signaling pathway that contributes to the severity ... sticky mucus to build up in the lungs and digestive ... genetic diseases in children and young adults. , In the ...
... HRT use explain the trend, researchers say , FRIDAY, ... declining, especially among women over 50 who have estrogen ... the reason why. , After analyzing data on more ... that the decline may be linked with decreasing use ...
Cached Medicine News:Health News:AADR presents honorary membership to Senator Tom Harkin 2Health News:Poll: Hypothetical anthrax attack and antibiotics 2Health News:Poll: Hypothetical anthrax attack and antibiotics 3Health News:Poll: Hypothetical anthrax attack and antibiotics 4Health News:Poll: Hypothetical anthrax attack and antibiotics 5Health News:Poll: Hypothetical anthrax attack and antibiotics 6Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 2Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 3Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 3
... of the ELECTRA 1400C are designed to ... walkaway capabilities. This system includes automated primary ... and factor assays in a single setup. ... and automatic preparation of reference curves and ...
... to maximize your testing options even when ... fully automated system offers superior technology, such ... to ensure testing accuracy and efficiency in ... backed by our high-quality service to help ...
... The SYNCHRON CX9 ALX system is ... time-consuming manual processes by as much as ... lower your total costs. Featuring the AccuSense® ... and an expanded test menu, the CX9 ...
... SYNCHRON CX4-S system consolidates DATs, ... in one workstation, targeted to ... 50-200 samples per day. Like ... the CX4-S is easy to ...
Medicine Products: